Skip to main content

Table 4 Performance metrics for the best performing fingerprint-based classification models

From: FP-ADMET: a compendium of fingerprint-based ADMET prediction models

Endpoint

FP

Calibration

Validation

BACC

AUC

BACC

AUC

Blood brain barrier

PUBCHEM

0.82

0.90

0.81

0.92

Oral bioavailability

PUBCHEM

0.71

0.77

0.71

0.78

Anticommensal effect

PUBCHEM

0.76

0.82

0.74

0.81

CYP450 (1A2)

PUBCHEM

0.85

0.93

0.85

0.93

CYP450 (2C19)

ECFP4

0.81

0.88

0.81

0.89

CYP450 (2C9)

PUBCHEM

0.78

0.88

0.79

0.89

CYP450 (2D6)

FCFP4

0.73

0.86

0.73

0.87

CYP450 (3A4)

FCFP6

0.80

0.89

0.80

0.90

CYP450 (2C8)

PUBCHEM

0.79

0.89

0.77

0.90

HIA

MACCS

0.84

0.89

0.83

0.89

BCRP inhibition

FCFP4

0.89

0.95

0.90

0.96

Metabolic intrinsic clearance

FCFP4

0.74

0.82

0.74

0.84

Human liver microsomal stability

AT2D

0.77

0.83

0.77

0.84

PGP inhibitor

PUBCHEM

0.84

0.91

0.85

0.92

PGP substrate

ASP

0.80

0.87

0.80

0.88

DMSO solubility

ECFP2

0.72

0.78

0.73

0.80

Phosphate buffer solubility

PUBCHEM

0.79

0.87

0.79

0.87

Skin sensitization (LLNA)

PUBCHEM

0.69

0.76

0.67

0.74

Skin sensitization (KeratinSens)

LSTAR

0.64

0.65

0.57

0.60

Skin sensitization (HRIPT)

ECFP0

0.70

0.74

0.67

0.72

Skin sensitization (hCLAT)

MACCS

0.65

0.70

0.61

0.68

Skin sensitization (DPRA)

FCFP4

0.68

0.72

0.68

0.72

Rat acute oral toxicity (\(\text {LD}_{{50}}\))

PUBCHEM

0.69

0.78

0.68

0.81

AMES mutagenecity

PUBCHEM

0.79

0.86

0.79

0.87

Cytotoxicity (HepG2)

AT2D

0.78

0.85

0.78

0.85

Cytotoxicity (CRL-7250 cell line)

AT2D

0.79

0.87

0.78

0.86

Cytotoxicity (HACAT cell line)

AT2D

0.77

0.85

0.77

0.85

Cytotoxicity (HEK cell line)

PUBCHEM

0.77

0.87

0.76

0.86

Cytotoxicity (NIK cell line)

PUBCHEM

0.78

0.87

0.78

0.87

DILI

PUBCHEM

0.78

0.86

0.79

0.88

Hemolytic toxicity (saponins)

FCFP6

0.84

0.88

0.85

0.90

hERG cardiotoxicity

FCFP6

0.79

0.86

0.80

0.88

hERG liability

PUBCHEM

0.76

0.87

0.76

0.88

Mitochondrial toxicity

PUBCHEM

0.79

0.90

0.77

0.90

Urinary tract toxicity

FCFP4

0.71

0.77

0.70

0.73

Phototoxicity in vitro

KR

0.70

0.76

0.69

0.80

Phototoxicity human

PUBCHEM

0.69

0.75

0.67

0.75

Toxic myopathy

DFS

0.68

0.74

0.63

0.74

Myelotoxicity

FCFP4

0.72

0.79

0.71

0.80

phospholipidosis

FCFP2

0.78

0.86

0.77

0.88

Cholestasis

RAD2D

0.67

0.73

0.67

0.74

Rhabdomyolysis

MACCS

0.71

0.80

0.70

0.83

Respiratory toxicity

MACCS

0.82

0.88

0.82

0.89

Ototoxicity

PUBCHEM

0.69

0.74

0.67

0.72

MATE1

DFS

0.64

0.67

0.65

0.65

Hepatic steatosis

MACCS

0.63

0.67

0.59

0.68

Carcinogenecity

PUBCHEM

0.67

0.71

0.68

0.75

OATP1B1 inhibition

ECFP6

0.72

0.80

0.73

0.82

OATP2B1 inhibition

ECFP6

0.67

0.68

0.65

0.70

OATP1B3 inhibition

PUBCHEM

0.74

0.83

0.77

0.87

BSEP inhibition

ECFP4

0.85

0.93

0.88

0.95

OCT2 inhibition

PUBCHEM

0.73

0.81

0.73

0.79

PPB

PUBCHEM

0.82

0.92

0.84

0.92

Elimination half-life Human

ASP

0.75

0.86

0.76

0.88

Elimination half-life Mouse

ECFP2

0.74

0.86

0.72

0.84

Elimination half-life Rat

KR

0.74

0.86

0.74

0.83

  1. The values reported are the balanced accuracies (BACC) and area under the ROC curve (AUC) (average of 3 independent runs) for the calibration/validation sets